OncLive SOSS

Authors

Latest:

Surgical Intervention Provides the Foundation for Exploring Immunotherapy in Glioblastoma

Because the current standard-of-care modalities have significant limitations, there has been a great interest in pursuing immunotherapeutic strategies for glioblastoma.

Melina Elpi Marmarelis, MD

Latest:

How Biomarker Testing Could Continue to Evolve in NSCLC

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.

Katherine Wang, MD

Latest:

Dr Wang on the Role of Active Surveillance in Patients With Renal Masses

Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.

David Olmos, MD, PhD

David Olmos, MD, PhD, a medical oncologist, group leader, and distinguished investigator, Genetic, Genomics & Therapeutics in Prostate Cancer, at Instituto de Investigación Hospital 12 de Octubre in Madrid.

Latest:

Dr Olmos on Evaluating HRR Alterations in mHSPC

David Olmos, MD, PhD, discusses the evaluation of homologous recombination repair alterations in metastatic hormone-sensitive prostate cancer.

Shambavi Richard, MD

Latest:

Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple Myeloma

Various immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.

Karin A. Skalina, MD, PhD

Latest:

Precision Cancer Care: Preserving Normal Tissue With Proton Therapy

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

Jacob Shreve, MD, MS

Latest:

The Medical AI Revolution

We consider artificial intelligence hype vs reality, focusing on predictive modeling to answer medical questions about diagnosis, treatment choice, etc.

Rupert Bartsch, MD

Latest:

Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain Metastases

Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.

John Michael Kaczmar, MD

Latest:

Dr Kaczmar on the Future Utility of Cemiplimab With Fianlimab in Advanced Melanoma

John Michael Kaczmar, MD, discusses future implications for the use of fianlimab in combination with cemiplimab for the treatment of patients with advanced melanoma.

Kian-Huat Lim, MD, PhD

Latest:

Dr Lim on Multidisciplinary Approaches to Pancreatic Cancer Management

Kian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.

Aaron E. Katz, MD

Latest:

Dr Katz on a Cystoscopic Cryocatheter in Bladder Cancer

Aaron E. Katz, MD, discusses the rationale for and findings from a preclinical study evaluating the efficacy of a novel cystoscopic cryocatheter for in situ bladder cancer destruction.

Barbara Ann Karmanos Cancer Institute

Latest:

Barbara Ann Karmanos Cancer Institute and Wayne State University Name Boris C. Pasche, MD, PhD, FACP, President and Chief Executive Officer

The Barbara Ann Karmanos Cancer Institute, part of Grand Blanc-based McLaren Health Care and a National Cancer Institute-designated Comprehensive Cancer Center, in conjunction with Wayne State University, have named Boris C. Pasche, MD, PhD, FACP, President & Chief Executive Officer and Chair of the Department of Oncology at the Wayne State University School of Medicine.

Bradley D. Hunter, MD

Latest:

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Yi-Bin Chen, MD

Latest:

Insights Into Real-World Evidence in Chronic GVHD

Panelists discuss how real-world evidence shows lower response rates and shorter time to next treatment compared to clinical trials due to more advanced patient populations and different monitoring practices, while highlighting the potential value of combination therapies using multiple FDA-approved agents simultaneously despite the lack of formal trial data supporting such approaches.

Kristen M. O’Dwyer, MD

Latest:

Health Care Resource Utilization and Transition of Care

Panelists discuss routine laboratory monitoring for cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) as well as insights from the American Society of Hematology Annual Meeting and Exposition (ASH 2024) data on health care resource utilization and costs associated with administering chimeric antigen receptor (CAR) T-cell therapy and managing related toxicities.

Ryan Hickey, MD, New York University Langone Health

Latest:

Rapid Readouts: Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized, multicentre, open-label phase 2 trial

Ryan Hickey, MD, presents data from the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium on results of the phase 2 DOSISPHERE-01 trial of personalized vs standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma.

Latest:

Dr Amini on High-Risk Factors Associated With Cardiac Toxicities in Lung Cancer

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.

Xianxin Hua, MD, PhD

Latest:

Investigators Explore Immunotherapy for NETs as Incidence Grows

To date, oncologists have not seen much success with immunotherapy for neuroendocrine tumors.

Gurdeep Parmar, MBBS, MD, FRCPA, FRACP

Latest:

Isatuximab Subcutaneous (ISA SC) via On-Body Injector (OBI) or Manual Injection For Relapsed/Refractory Multiple Myeloma (RRMM): Patient Experience From the Phase 2 IZALCO Study

Gurdeep Parmar, MBBS, MD, FRCPA, FRACP, discusses patient experience and preference findings from the phase 2 IZALCO study evaluating subcutaneous isatuximab administered via on-body injector in relapsed/refractory multiple myeloma.

Christina L. Roland, MD, MS, FACS

Latest:

Dr Roland on a Study of Neoadjuvant Immune-Checkpoint Blockade Across Sarcoma Subtypes

Christina L. Roland, MD, MS, FACS, discusses a study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma.